Daxor Corporation (NASDAQ:DXR) Sees Large Decrease in Short Interest

Daxor Corporation (NASDAQ:DXR) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 1,276 shares, a decrease of 38.7% from the June 15th total of 2,083 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 3,122 shares, the short-interest ratio is presently 0.4 days.

Daxor Trading Up 1.9%

Shares of DXR traded up $0.20 during mid-day trading on Friday, reaching $10.71. The stock had a trading volume of 4,772 shares, compared to its average volume of 2,078. Daxor has a 52-week low of $8.56 and a 52-week high of $14.76. The business’s fifty day moving average is $10.38 and its 200 day moving average is $11.23.

Daxor (NASDAQ:DXR) last issued its earnings results on Monday, March 2nd. The company reported ($0.10) EPS for the quarter.

Institutional Trading of Daxor

Several institutional investors have recently made changes to their positions in the company. Aristides Capital LLC purchased a new position in Daxor in the first quarter worth approximately $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Daxor in the 1st quarter valued at $245,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Daxor during the 4th quarter worth $184,000. Crescent Grove Advisors LLC purchased a new position in shares of Daxor during the 1st quarter worth $104,000. Finally, Osaic Holdings Inc. acquired a new stake in shares of Daxor during the 2nd quarter worth about $86,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.